drugset / Trial / NCT06527222

A Study of Ranolazine in ALS

NCT06527222

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to evaluate safety, effect on cramps, function and quality of life of ranolazine versus placebo for the treatment of ALS.

Timeline

Start
2025-04-29
Primary completion
2028-07
Completion
2028-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Ranolazine Small molecule 500 mg Oral
Subject Ranolazine Small molecule 1000 mg Oral